Assessment of the Phototoxic Potential of LEO 29102 Cream

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00958516
Recruitment Status : Completed
First Posted : August 13, 2009
Last Update Posted : October 25, 2013
Information provided by (Responsible Party):
LEO Pharma

Brief Summary:
The purpose of this trial is to evaluate the phototoxic potential of a single application on healthy skin of LEO 29102 cream in different doses.

Condition or disease Intervention/treatment Phase
Atopic Dermatitis Drug: LEO 29102 cream Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Official Title: A Phase 1 Study Evaluating the Phototoxic Potential of LEO 29102 Cream (2.5 mg/g, 1.0 mg/g, 0.3 mg/g, 0.1 mg/g, 0.03 mg/g) and the Cream Vehicle, Applied on Intact Skin of Healthy Male Subjects
Study Start Date : September 2009
Actual Primary Completion Date : October 2009
Actual Study Completion Date : October 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: LEO 29102 cream Drug: LEO 29102 cream
LEO 29102 cream in different doses and the cream vehicle

Primary Outcome Measures :
  1. Phototoxic reaction according to the investigator's assessment [ Time Frame: 5 days ]

Secondary Outcome Measures :
  1. Clinical scoring and other skin reactions [ Time Frame: 5 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects having understood and signed an informed consent form
  • Male adults between the age of 18 and 65 years (both inclusive)
  • Healthy subjects without signs of skin irritation on test areas (erythema, dryness, roughness or scaling)
  • Subjects willing and able to follow all the study procedures and complete the whole study
  • Subjects affiliated to a social security system

Exclusion Criteria:

  • Females
  • Males who are not willing to use a local contraception for the entire duration of the study, and refrain from fathering a child within 3 months following the study drug
  • Systemic treatments which may interfere with the inflammatory reaction (e.g., corticosteroids and other anti-inflammatory drugs) within 2 weeks prior to randomisation
  • Systemic or topical treatments suspected of causing photobiological reactions (e.g., tetracycline, thiazides, fluoroquinolones) within 4 weeks prior to randomisation
  • Exposure to excessive or chronic UV radiation (i.e., sunbathing, solarium, phototherapy) within 4 weeks prior to inclusion or is planned during the study period
  • Dark pigmentation of the skin or skin type that may, in any way, confound interpretation of the study results (skin types V and VI on the Fitzpatrick scale)
  • Scars, moles, sunburn or other blemishes in the test area which may interfere with grading
  • Any systemic or cutaneous disease on the test area that may confound interpretation of the study results (e.g., atopic dermatitis, eczema, psoriasis)
  • Relevant history of or concurrent photo-induced or photo-aggravated disease (abnormal response to sunlight
  • Subjects with a history of serious allergy, allergic skin rash or known sensitivity to any component of the investigational products
  • Subjects who have received treatment with any non-marketed drug substance (i.e., an agent which has not yet been made available for clinical use following registration) within the last four (4) weeks before randomisation
  • Participation in any other current interventional clinical trial based on interview of the subject
  • Previously randomised in this trial
  • Subjects impossible to contact in case of emergency
  • Subjects known or, in the opinion of the investigator, are unlikely to comply with the Clinical Study Protocol (e.g. alcoholism, drug dependency or psychotic state)
  • Subjects who are in an exclusion period in the National Biomedical Research Register of the French Ministry of Health
  • Subjects under guardianship, hospitalised in a public or private institution for a reason other than research or subject deprived of freedom

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00958516

LEO Pharma site
St Quentin en Yvelines Cedex, France, 78054
Sponsors and Collaborators
LEO Pharma
Study Director: Director International Clinical Development, MD LEO Pharma

Responsible Party: LEO Pharma Identifier: NCT00958516     History of Changes
Other Study ID Numbers: LEO 29102-C02
EudraCT Number 2009-011177-32
First Posted: August 13, 2009    Key Record Dates
Last Update Posted: October 25, 2013
Last Verified: October 2013

Keywords provided by LEO Pharma:

Additional relevant MeSH terms:
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases